Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
for Recurrent B-Cell Non-Hodgkin Lymphoma
Drug: Epcoritamab
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18+
Code: NCT07283679·Phase 1, Phase 2·Recruiting·Listed Dec 2025